Head and Neck Cancer - Innovatives to Change the Face of Treatment

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2005-02-02

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The incidence of head and neck cancers is increasing. Surgery and radiation are employed with curative intent for early stage lesions. Chemotherapy concurrent with radiation and surgery is the treatment of choice for unresectable disease. The market is characterized by a significant need for agents that reduce tumor size, curtail the extent of resection and delay or prevent tumor recurrence.


Scope

  • Overview of the main tumor types for head and neck cancer including epidemiology and staging
  • Current treatment options by tumor site and stage, with assessment of clinical controversies
  • Key recommendations in the areas of greatest unmet need including the need for improvements in quality of life as well as increased survival
  • Profiles of key head and neck therapies in late stage development including forecasts of Erbitux, Iressa, and Advexin


    • Report Highlights
    Platinum based therapy combined with radiation remains the standard of care for advanced stage patients. The survival advantage of this combination is not outstanding and is characterized by its toxicity. Therefore agents that provide even moderate improvements can expect significant uptake.

    Imclone/BMS/KGaA's Erbitux holds the most promise for head and neck cancer patients but cost may limit its uptake.

    Future developments for head and neck cancer will require integration of targeted therapy into current radiation and chemotherapy regimes. Key trials are examined.


    Reasons to Purchase

  • Identify market opportunities by exploring current unmet needs and key requirements for improving survival in head and neck cancer
  • Understand the market impact of innovative therapies such as Imclone/BMS/ Merck KGaA's Erbitux
  • Plan product development based on an understanding of physician expectation of new therapies integration into current treatment regimes

    • Table of Contents

    Other users found this report page using the following search terms: head and neck neck cancer head innovatives face epidemiology treament chemo cancers joint

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.